Advanced Proteome Therapeutics (STU:0E81) Total Equity: €-0.02 Mil (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Total Equity?

Advanced Proteome Therapeutics STU:0E81 Total Equity is €-0.02 Mil as of Apr. 2023.

Advanced Proteome Therapeutics's total equity for the quarter that ended in Apr. 2023 was €-0.02 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Advanced Proteome Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Total Equity Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -0.82 -1.20 -1.74 -0.84

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.07 -0.84 -0.87 -1.05 -0.02

Advanced Proteome Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Advanced Proteome Therapeutics's Total Equity for the fiscal year that ended in Jul. 2022 is calculated as

Total Equity=Total Assets(Q: Jul. 2022 )-Total Liabilities(Q: Jul. 2022 )
=0.625-1.462
=-0.84

Advanced Proteome Therapeutics's Total Equity for the quarter that ended in Apr. 2023 is calculated as

Total Equity=Total Assets(Q: Apr. 2023 )-Total Liabilities(Q: Apr. 2023 )
=0.057-0.077
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-0.02 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a Total Equity of €-0.02 Mil as of Apr. 2023. The total amount of equity as record on a company's balance sheet. View historical data for Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Total Equity too high?
Advanced Proteome Therapeutics' current Total Equity is €-0.02 Mil.
How does Advanced Proteome Therapeutics' Total Equity compare to VRTX and REGN?
Advanced Proteome Therapeutics' Total Equity of €-0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Total Equity is €-0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Total Equity of €-0.02 Mil. The current Total Equity is €-0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Total Equity is €-0.02 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.